ADAP - The Buzz Show: Adaptimmune Therapeutics plc (NASDAQ: ADAP) Strategic Collaboration with Genentech

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adaptimmune Therapeutics plc on the Rise After Entering into a Strategic Collaboration with Genentech”

Adaptimmune Therapeutics (NASDAQ: ADAP) plc climbed over 23% in premarket trading after the company entered into a strategic collaboration and license agreement with Genentech.

The collaboration will seek to develop and commercialize allogeneic cell therapies to treat multiple oncology indications and covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform.

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

For more information, please visit: Adapimmune Therapeutics plc

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Adaptimmune Therapeutics plc (NASDAQ: ADAP) Strategic Collaboration with Genentech first appeared on Financial Buzz .

For further details see: